summari ew report underli revenu
underli miss consensu
top estim underli adj ep
beat consensu estim
ew underli global thv transcathet heart valv sale
underli fell short consensu
shi expect thv
growth reflect mid-teen tavr transcathet aortic valv
replac growth us market growth ou
ew saw modest y/i share loss europ addit ew
lower thv guidanc around due
limit expect contribut transcathet mitral/tricuspid
revis launch strategi sapien ultra given
perform thv busi ytd steep
acceler impli previou guidanc higher-end
surpris us ew lower thv
outlook broadli ew left total underli sale growth
guidanc unchang maintain expect
report sale higher-end guidanc rang
bottom line ew maintain adj ep guidanc
report ew guid total sale
report adj ep
report pipelin front notabl
updat view announc pivot trial
ew pascal
dmr
estim chang rais sale estim
underli rais adj ep estim
report lower sale estim
underli adj ep
estim report maintain price
target assum cash ep
continu next page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
thv miss street expect underli ww thv sale came
street expect estim tavr front ew
estim ww procedur grew mid-teen compani growth lower due ou
dynam regard us market manag said procedur growth roughli line ew
growth mid-teen ou outsid us ew said tavr procedur grew low double-
digit europ specif ew estim market procedur growth mid-teen spread
broadli across countri ew note modest share loss europ year-over-year basi
manag said europ share posit stabil q/q base compani commentari
estim ew us tavr sale ou sale underli
estim ew tavr sale europ low-single-digit growth japan tavr
sale get insight ou market dynam report earn
novemb ew re-affirmed full-year thv guidanc higher-end
rang expect underli growth rang vs higher-end due
expect limit contribut cardioband revis launch strategi sapien ultra see text
full-year guidanc compar ytd thv growth
ew launch ultra control manner contribut expect minim ew
expect sapien ultra ce mark approv fda approv around year-end consist
previou expect howev ew comment roll-out ultra control focu
physician train patient outcom ew expect minim contribut
product separ manag said feedback self-expand centera devic remain
posit recal ew resum commerci implant europ initi pivot trial earlier
suppli constraint continu impact cardioband pascal pivot trial dmr
announc ew record cardioband sale due on-going suppli constraint mitral
tricuspid manag expect suppli issu continu improv progress
throughout next year address problem ew move manufactur facil
chang part suppli chain regard pascal manag said remain track
commerci launch europ separ notabl pipelin highlight view
announc pascal pivot trial clasp ii dmr indic ew said studi
random control trial vs abt mitraclip devic dmr patient deem inoper local
heart team non-inferior studi expect enrol around patient across site featur
primari endpoint mr grade reduct secondari endpoint major advers event
shv growth driven inspiri intuiti elit ew report shv surgic heart valv sale
underli consensu estim result
driven solid aortic unit volum growth continu adopt ew premium surgic heart
valv product inspiri intuiti elit ew also announc japan launch inspiri last month
follow reimburs approv ew re-affirmed underli growth expect shv
busi continu expect shv sale come toward higher-end
critic growth acceler ew report critic cc sale
underli beat consensu estim result driven strong perform
across product line led compani hemospher advanc monitor platform cc
busi particularli strong aid new gpo group purchas organ contract ew
expect critic care underli growth exceed top-end full-year guidanc rang
post full-year cc sale higher-end guidanc rang
top-lin outlook adj ep maintain thv guidanc lower call ew
re-affirmed underli sale growth outlook addit manag continu
expect total sale come toward higher-end guidanc rang report
basi thv ew expect sale higher-end rang expect underli
growth around vs higher-end previous ew expect shv sale
higher-end rang underli cc come higher-end
rang exceed higher-end underli guidanc regard currenc
impact sale fx expect tailwind chang vs prior guidanc
move ew reiter guidanc follow item gross margin
sg spend sale spend sale ew continu expect
tax rate lower end previou guidanc excl special item bottom
line ew maintain adj ep guidanc report ew guid
total sale report adj ep
compani report secur llc estim
price target nc
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
edward lifesci incom statementin million except per share good sold excl gross oper oper expens expens incom pre-tax debt net adj dilut analysi gross oper growthnet medic technolog
